HI-Tech Pharmacal presses for US exclusivity on generic Cosopt
This article was originally published in Scrip
Executive Summary
Hi-Tech Pharmacalis continuing its efforts to have the US FDA confirm that it is legally entitled to 180 days of marketing exclusivity for its generic version of Merck & Co's glaucoma treatment Cosopt (dorzolamide plus timolol ophthalmic solution).